Equities research analysts expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to announce earnings per share (EPS) of ($0.09) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics posted earnings per share of ($0.03) during the same quarter last year, which indicates a negative year over year growth rate of 200%. The firm is scheduled to issue its next earnings results on Thursday, March 29th.

According to Zacks, analysts expect that Brainstorm Cell Therapeutics will report full-year earnings of ($0.37) per share for the current financial year. For the next fiscal year, analysts expect that the firm will report earnings of ($0.42) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings data on Tuesday, October 17th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.03. During the same period in the previous year, the business posted ($0.09) EPS.

Separately, Maxim Group set a $9.00 price objective on Brainstorm Cell Therapeutics and gave the company a “buy” rating in a research note on Monday, October 16th.

Several institutional investors have recently made changes to their positions in the stock. Sphera Funds Management LTD. purchased a new position in shares of Brainstorm Cell Therapeutics in the 2nd quarter valued at about $2,759,000. Vanguard Group Inc. boosted its holdings in Brainstorm Cell Therapeutics by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock worth $2,733,000 after buying an additional 17,657 shares during the last quarter. Finally, KCG Holdings Inc. boosted its holdings in Brainstorm Cell Therapeutics by 4.6% in the 1st quarter. KCG Holdings Inc. now owns 41,537 shares of the biotechnology company’s stock worth $177,000 after buying an additional 1,820 shares during the last quarter. Hedge funds and other institutional investors own 12.89% of the company’s stock.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) traded down $0.09 during midday trading on Friday, hitting $3.98. The company’s stock had a trading volume of 49,878 shares, compared to its average volume of 134,298. Brainstorm Cell Therapeutics has a twelve month low of $2.07 and a twelve month high of $5.18.

ILLEGAL ACTIVITY NOTICE: “Brainstorm Cell Therapeutics Inc. (BCLI) Expected to Post Earnings of -$0.09 Per Share” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/01/brainstorm-cell-therapeutics-inc-bcli-expected-to-post-earnings-of-0-09-per-share.html.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get a free copy of the Zacks research report on Brainstorm Cell Therapeutics (BCLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.